Flying surgical robot aims for mid-2026

A flying surgical robot aims to slash time to care on the battlefield.

SS Innovations, the India-based maker of the SSi Mantra robotic system, announced a bold new direction this spring, a concept drone called Vimana Aero that could deliver telerobotic-assisted surgical care from the air. The company’s chief executive, Dr. Sudhir Srivastava, describes the project as part of a broader push to move beyond ground-based robotics and shrink the window between injury and treatment. He described to industry outlets that the Indian Army approached SS Innovations with a stark problem, hemorrhage as the leading cause of death when casualties cannot be evacuated quickly enough, and challenged the team to reimagine how care gets to the point of injury. The concept design, unveiled in April, blends SS Innovations’ teleconnectivity with surgical robotics to create a flying platform that could, in theory, bring specialized care to austere or hostile environments rather than waiting for a conventional hospital transfer.

Srivastava’s framing is telling: the Vimana Aero is one of the company’s “crazy, disruptive ideas” to broaden access to telerobotic care, a mindset he described with a practical twist, “science must progress.” The drone concept is meant to partner with SS Innovations’ existing family of robotic systems rather than replace them, offering a path to reach patients who would otherwise be out of reach for traditional care chains. The Vimana Aero is positioned as a feasibility testbed, an engineering system to prove whether flight-enabled telepresence and robotic control can be integrated into a medical workflow without sacrificing safety or precision. The plan is not just to fly a camera, but to fly a capable platform enabling remote surgical or near-surgical intervention under appropriate oversight, with the goal of narrowing the injury-to-care timeline.

In a parallel track, SS Innovations has already made real-world progress with its ground-based Mantra line. The company launched SSi Mantra in 2021 and has since installed more than 200 systems, performing almost 11,000 surgeries across its installed base. SS Innovations highlights long-distance capability, noting 20 cardiac telesurgeries as part of its operational pedigree. Documentation indicates that the Mantra family has earned regulatory approvals in 14 countries, underscoring a track record of safety and regulatory alignment in multiple markets. The company reports that the next generation, SSi Mantra 3, has been submitted to the U.S. Food and Drug Administration for 510(k) clearance, signaling ongoing intent to expand in the United States and potentially broaden use cases for teleoperation in complex procedures.

From an engineering standpoint, the Vimana Aero concept raises a cluster of constraints that practitioners will want to watch. First, flight time and energy use must be balanced against the payload of surgical tools and the weight of a sterile field kit; the more capable the robotic end-effectors, the heavier the drone and the greater the endurance challenge. Second, real-time control for surgery depends on ultra-reliable, low-latency communications; any jitter or dropouts could undermine precision in a critical moment. Third, integrating an airborne platform with a medical workflow invites regulatory scrutiny that spans aviation, medical device, and telepresence standards, a complexity the company is already navigating for its Mantra line in ground-based deployments. Finally, field deployments in conflict or remote regions demand ruggedization, rapid maintenance cycles, and proven sterilization and infection-control workflows, areas where the transition from a lab sketch to a live clinical scenario is nontrivial.

If the Vimana Aero advances toward a functional prototype by mid-2026, the real test will be whether the airborne approach delivers measurable improvements in survival and recovery times in controlled pilots. The Mantra rollout provides a concrete reference point, a mature, multi-country platform with thousands of procedures and a clear regulatory pathway, even as a newer airborne concept contends with added layers of complexity. The industry will be watching not only the technical feasibility but the compelling clinical and logistical evidence that a drone can meaningfully augment, or even redefine, the time-to-treatment curve for surgical care.